Education
About Us
Working with TipRanks
Follow Us
Organon (OGN)
NYSE:OGN
Earnings Data
Report Date
Aug 12, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
0.94Last Year’s EPS
1.12Same Quarter Last Year
Based on 8 Analysts Ratings
Earnings Call Summary
Earnings Call Date:May 01, 2025
|% Change Since: -34.65%
|Next Earnings Date:Aug 12, 2025
Earnings Call Sentiment|Neutral
The earnings call presented a mix of strong growth in certain key products and segments, alongside challenges such as revenue decline due to loss of exclusivity and pricing pressures. The company's focus on cost efficiency and deleveraging initiatives is aimed at strengthening its financial position. While there are positive developments such as the successful launch and growth of certain products, the financial challenges and external pressures balance the overall sentiment.Company Guidance
During the Organon First Quarter 2025 Earnings Call, the company provided financial guidance and performance metrics for the year. Organon expects Nexplanon to achieve over $1 billion in revenue for 2025, while Vtama is anticipated to generate $150 million. The company's restructuring initiatives are projected to yield approximately $200 million in annual savings. Organon is affirming its guidance for revenue and adjusted EBITDA margin, with a target of generating over $900 million in free cash flow before one-time costs. The dividend payout has been reset, enabling the company to redirect almost $200 million towards debt reduction, aiming for a net leverage ratio below 4 by year-end. The company also highlighted a 12% growth in the women's health franchise and a 26% increase in fertility revenue. Additionally, Organon noted a 20% growth in Jada and a 57% increase in Hadlima sales in the first quarter. The guidance reflects the company's efforts to manage leverage and focus on growth, despite macroeconomic uncertainties and potential tariff impacts.Strong Growth in Key Products
Nexplanon grew double-digit, set to achieve more than $1 billion in revenue in 2025. Vtama launch successful, expected to reach $150 million in revenue for the year. Fertility segment grew nearly 26% globally.
Cost Efficiency and Deleveraging Initiatives
Restructuring initiatives expected to yield $200 million in annual savings. Dividend payout reset to prioritize debt reduction, enabling a path to achieve a net leverage ratio below 4 by year-end.
Biosimilars Segment Growth
Hadlima grew 57% in the first quarter with strong uptake in the U.S. Acquired rights for Tofidence in the U.S., with potential for future sales growth.
Expansion and Launch Plans
Jada launched in South Korea, achieved CE Mark of approval in Europe. Plans to launch in select EU markets this year.
OGN Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
OGN Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 01, 2025 | $12.90 | $9.43 | -26.90% |
Feb 13, 2025 | $14.40 | $15.99 | +11.04% |
Oct 31, 2024 | $17.26 | $18.08 | +4.75% |
Aug 06, 2024 | $19.17 | $17.70 | -7.67% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Organon (OGN) report earnings?
Organon (OGN) is schdueled to report earning on Aug 12, 2025, TBA Not Confirmed.
What is Organon (OGN) earnings time?
Organon (OGN) earnings time is at Aug 12, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is OGN EPS forecast?
OGN EPS forecast for the fiscal quarter 2025 (Q2) is 0.94.